Edition:
India

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

3,024.00GBp
23 Feb 2018
Change (% chg)

-13.00 (-0.43%)
Prev Close
3,037.00
Open
3,062.00
Day's High
3,125.00
Day's Low
3,002.00
Volume
2,475,907
Avg. Vol
3,205,937
52-wk High
5,067.00
52-wk Low
2,940.50

Chart for

About

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas... (more)

Overall

Beta: 1.54
Market Cap(Mil.): £35,231.62
Shares Outstanding(Mil.): 908.51
Dividend: 3.85
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.91 10.66
ROE: -- 16.41 14.30

BRIEF-FDA Accepts Shire's Biologics License Application

* FDA ACCEPTS SHIRE'S BIOLOGICS LICENSE APPLICATION AND GRANTS PRIORITY REVIEW FOR LANADELUMAB FOR PREVENTION OF ATTACKS IN HEREDITARY ANGIOEDEMA PATIENTS​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

23 Feb 2018

BRIEF-Shire Announces FDA Acceptance Of sBLA For Cinryze For Pediatric Hereditary Angioedema Use

* SHIRE ANNOUNCES FDA ACCEPTANCE OF SBLA FOR CINRYZE® FOR PEDIATRIC HEREDITARY ANGIOEDEMA USE

15 Feb 2018

UPDATE 2-Shire ‍sees slowdown in earnings growth as generic rivals bite

* Shares pare losses to trade broadly flat (Adds further CEO comments, reaction, updates shares)

14 Feb 2018

Shire ‍posts 16 pct rise in full-year earnings, sees slower growth in 2018

LONDON, Feb 14 Shire, the pharma firm splitting its rare disease and hyperactivity drugs into two units, said sales would grow in the mid-single digits and profits by a lower percentage than the top line this year after earnings per share rose 16 percent in 2017.

14 Feb 2018

BRIEF-Shire Says Granted Orphan Drug Status For Crohn's Disease Treatment For Children

* SHIRE - U.S. FDA GRANTS ORPHAN DRUG DESIGNATION FOR INVESTIGATIONAL SHP647 FOR TREATMENT OF PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

13 Feb 2018

BRIEF-AB Biosciences And Shire Enter Into Agreement

* AB BIOSCIENCES AND SHIRE ENTER INTO AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF AB BIOSCIENCES' PRIM PROGRAM

30 Jan 2018

BRIEF-Shire Says ‍Thomas Dittrich Will Assume Role As CFO

* ‍THOMAS DITTRICH WILL ASSUME HIS ROLE AS CHIEF FINANCIAL OFFICER​

19 Jan 2018

BRIEF-Shire Says Granted EU marketing Authorization For ADYNOVI For Adults And Adolescents With Hemophilia A

* SHIRE GRANTED EU MARKETING AUTHORIZATION FOR ADYNOVI [ANTIHEMOPHILIC FACTOR (RECOMBINANT), PEGYLATED] FOR ADULTS AND ADOLESCENTS WITH HEMOPHILIA A​

15 Jan 2018

Shire cuts 2020 revenue target, prepares for spin-off of ADHD drugs

LONDON Shire ditched its revenue target of $20 billion by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance.

09 Jan 2018

UPDATE 1-Shire to separate ADHD drugs before possible spin-off, cuts 2020 target

LONDON, Jan 8 London-listed pharmaceutical group Shire said on Monday it would create two distinct business units for its rare disease and hyperactivity medicines before deciding later this year whether to spin off the latter into a separately listed group.

08 Jan 2018

Earnings vs. Estimates